Asthma drug roflumilast tested for Long-Term safety in 150 patients
NCT ID NCT00246922
First seen Feb 20, 2026 · Last updated May 17, 2026 · Updated 13 times
Summary
This study looked at the long-term safety of the drug roflumilast in adults with asthma. It included 150 people who had already completed a 24-week study of the same drug. Participants took roflumilast once daily for an additional 28 weeks, for a total of 52 weeks. The goal was to gather more information on safety and how well the drug controls asthma over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIAL ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nycomed Japan and Mitsubishi Tanabe Pharma Corporation
Osaka, Japan
Conditions
Explore the condition pages connected to this study.